Panthera Biopartners

Panthera Biopartners is an independent SMO (Site Management Organization) based in the United Kingdom. Founded in 2019, Panthera aims to revolutionize the clinical trial process by ensuring the right patient is matched with the right trial at the right time. The company, with the slogan "An independent SMO partner providing the right patient, for the right trial, at the right time," is focused on recruiting and retaining patients for clinical trials in various therapy areas, such as cardiac disease, allergies, migraine, osteoarthritis, osteoporosis, and diabetes. The team at Panthera, including co-founders Dr. Ian Smith and Professor John Lyon, brings a wealth of industry expertise to the table. Notably, Dr. Ian Smith was the founder of Synexus, the world's largest SMO. Panthera has recently received a £10.00M Series B investment on 20 April 2022, with backing from BGF and Baronsmead Venture Trusts. In addition to its focus on patient recruitment, Panthera is committed to leveraging innovative digital technologies to make clinical trials more accessible for patients, customers, and research staff. The company's clinical trial sites have been designed with the aim of providing a professional and superior experience for patients, ensuring accessibility, comfortable surroundings, and dedicated time with doctors and nurses. Furthermore, Panthera ensures that all trial processes are managed by fully qualified technical staff, and its professional team is GCP trained with considerable experience in the running of clinical trials and providing timely, accurate data.